Sfoglia per AUTORE
CALIFANO C
Collezione ASL Biella

  

Items : 6

Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial. in British journal of haematology / Br J Haematol. 2025 Feb;206(2):556-564. doi: 10.1111/bjh.19920. Epub 2024 Nov 27.

2025
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara
ASL Biella

Freilone R; Varettoni M; Ferrero S; Tani M; Sartori R; Merli M; Pietrantuono G; Musuraca G; Tosi P; Mannina D; Ferrante M; Gaidano G; Caravita di Toritto T; Rossi FG; Califano C; Curreli L; Cavallo F; Conconi A; Boccomini C; Dessi D; Castiglione A; Monaco F; Drandi D; Villivà N; Benevolo G;

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi in Blood

2024
ASL Biella

Ferrero S; Del Giudice I; Galimberti S; Gattei V; Marcheselli L; Genuardi E; Drandi D; Pironti M; Dogliotti I; Civita AM; Della Starza I; Assanto GM; Guerrini F; Bono C; Bomben R; Boccomini C; Farina L; Olivieri J; Arcaini L; Cavallo F; Ballerini F; Margiotta Casaluci G; Zilioli VR; Zanni M; Musuraca G; Merli A; Bianchi B; Bolis S; Pavone V; et alii...

Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) in Blood

2021
ASL Biella

Benevolo G; Ferrero S; Villivà N; Castiglione A; Monaco F; Boccomini C; Cabras MG; Califano C; Casula P; Cavallo F; Conconi A; Drandi D; Gaidano G; Gregorini AI; Felici S; Ferrante M; Mannina D; Molinari AL; Musto P; Musuraca G; Merli M; Sartori R; Tani M; Varettoni M; Vitolo U; Orsucci L;

NEXT GENERATION SEQUENCING PROVIDES NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA: BIOLOGICAL RESULTS FROM FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIAL in Haematologica

2021
ASL Biella

Genuardi E; Ferrero S; Della Starza I; Grassi S; Bomben R; Mantoan B; Drandi D; Dogliotti I; Alessandria B; Ferrante M; Ragaini S; Civita AM; Ghiggi C; Pulsoni A; Ronconi S; Merli M; Califano C; Castellino C; Bari A; Conconi A; De Novi LA; Del Giudice I; Gattei V; Galimberti S; Luminari S; Ladetto M; Federico M;

Clinical and molecular results of the phase II BRB (bendamustine, rituximab and bortezomib) trial of the fondazione italiana linfomi (FIL) for relapsed/refractory waldenström macroglobulinemia patients in Blood

2018
ASL Biella

Benevolo G; Ferrero S; Andriani A; Castiglione A; Baraldi A; Boccomini C; Cabras MG; Califano C; Cavallo F; Conconi A; Curreli L; Drandi D; Gaidano G; Felici S; Ferrante M; Mannina D; Merli M; Molinari AL; Musto P; Musuraca G; Rossi FG; Sartori R; Tani M; Varettoni M; Vitolo U; Orsucci L;

IELSG-38: A phase II study of chlorambucil in combination with rituximab followed by maintenance therapy with subcutaneous rituximab in patients with extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT) in Blood

2017
ASL Biella

Stathis A; Gregorini A; Gressin R; Orsucci L; Perrot A; Tani M; Coiffier B; Musuraca G; Guieze R; Marino D; Gini G; Ferrari A; Gyan E; Morschhauser F; Palombi F; Cavallo F; Gouill SL; Tilly H; Salvi F; Conconi A; Cabras MG; Capochiani E; Califano C; Molinari AL; Pulsoni A; Ielmini N; Luminari S; Cavalli F; Zucca E; et alii...